Nirogacestat Dosage
Medically reviewed by Drugs.com. Last updated on Jul 8, 2024.
Applies to the following strengths: 50 mg; 100 mg; 150 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Fibromatosis
150 mg orally twice a day
Duration of therapy: Until disease progression or unacceptable toxicity
Use: For the treatment of progressing desmoid tumors in patients who require systemic therapy
Renal Dose Adjustments
Renal dysfunction: Data not available
Liver Dose Adjustments
Dose Modifications for Elevated Liver Enzymes:
- Grade 2 increased ALT or AST (3 to 5 times the upper limit of normal [3 to 5 x ULN] or greater): Withhold therapy until ALT, AST, or both are resolved to less than 3 x ULN or baseline, and then restart therapy at 100 mg orally twice a day.
- Grade 3 or 4 increased ALT or AST (greater than 5 x ULN): Permanently discontinue
Dose Adjustments
DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
Diarrhea:
- Grade 3 or 4 diarrhea persisting for at least 3 days despite maximal medical therapy: Withhold therapy until resolved to grade 1 or less, or baseline, and then restart therapy at 100 mg orally twice a day.
Hypophosphatemia:
- Grade 3 or 4 hypophosphatemia persisting for at least 3 days despite maximal replacement therapy: Withhold therapy until resolved to grade 1 or less, or baseline, and then restart therapy at 100 mg orally twice a day.
Hypokalemia:
- Grade 3 or 4 hypokalemia despite maximal replacement therapy: Withhold therapy until resolved to grade 1 or less, or baseline, and then restart therapy at 100 mg orally twice a day.
DOSE MODIFICATIONS FOR OTHER SEVERE, LIFE-THREATENING, OR PERSISTENT INTOLERABLE GRADE 2 ADVERSE EVENTS:
- Withhold therapy until resolved to grade 1 or less, or baseline.
- Only restart therapy at dose of 100 mg orally twice a day after considering the potential benefit and likelihood of recurrence of the adverse reaction.
- Permanently discontinue treatment for recurrence of a severe or life-threatening adverse reaction upon rechallenge at the reduced dose.
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Hemodialysis: This drug is highly bound to plasma proteins and not expected to be dialyzable.
Peritoneal dialysis: Data not available
Other Comments
Administration advice:
- Administer each 150 mg dose of this drug as 3 tablets of 50 mg.
- Swallow each tablet whole; do not break, crush, or chew.
- This drug may be taken with or without food.
- If a dose is missed or vomited, instruct the patient to take the next dose at its scheduled time.
Storage requirements:
- Store at 20C to 25C (68F to 77F).
- Temperature excursions permitted between 15C to 30C (59F to 86F).
Monitoring:
- Dermatologic: For new non-melanoma skin cancers (at baseline and routinely during therapy)
- Endocrine: For signs and symptoms of ovarian toxicity
- Gastrointestinal: For severe diarrhea
- General: For drug interactions (regularly during therapy)
- Hepatic: Liver function tests (regularly during therapy)
- Metabolic: Phosphate and potassium levels (regularly during therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Patient Information).
- Notify your health care provider if sustained diarrhea occurs that does not respond to supportive care.
- This drug may cause ovarian toxicity and impair fertility, potentially even after discontinuation of treatment; inform your health care provider of any symptoms of ovarian toxicity, including hot flashes or menstrual irregularities.
- This drug may elevate liver enzymes; your health care provider should monitor liver function regularly.
- Contact your health care provider if any new or changing lesions occur on the skin as this drug may cause new non-melanoma skin cancers.
- This drug can cause electrolyte abnormalities which may require phosphate and/or potassium supplementation; seek medical attention if any symptoms of muscle pain or weakness occur.
- Inform your health care provider of all concomitant medications, including over-the-counter drugs.
- Breastfeeding is not recommended during treatment.
- Patients of childbearing potential:
- This drug may cause potential harm to a fetus.
- Notify your health care provider of a known/suspected pregnancy; stop taking this drug if you become pregnant.
- Females and males (with female partners of reproductive potential): Use effective contraception during treatment and for 1 week after the last dose.
More about nirogacestat
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.